Current Report Filing (8-k)
September 30 2019 - 6:12AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 24, 2019
|
INMUNE
BIO INC.
|
|
|
(Exact name of registrant
as specified in charter)
|
|
Nevada
|
|
001-38793
|
|
47-5205835
|
(State or other jurisdiction
|
|
(Commission File
Number)
|
|
(IRS Employer
|
of incorporation)
|
|
|
|
Identification No.)
|
1200
Prospect Street, Suite 525 La Jolla, CA 92037
(Address
of Principal Executive Offices) (Zip Code)
(858)
964 3720
(Registrant’s
Telephone Number, Including Area Code)
Not
Applicable
(Former
Name or Former Address, If Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common Stock
|
|
INMB
|
|
NASDAQ
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01 Regulation FD Disclosure
On
September 24, 2019, INmune Bio, Inc. (the “Company”) published a press release (the “Press Release”) announcing
that RJ Tesi, M.D., Co-Founder and CEO will be featured in an interview with multimedia financial reporter, Jason Lin discussing
the Company’s accomplishments.
A
copy of the Press Release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Exhibits 99.1 shall not be deemed
“filed” for purposed of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)
or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated into any filing of the Company
under the Securities Act of 1933, as amended, or the Exchange Act.
Item
9.01 Financial statements and Exhibits
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
INMUNE
BIO INC.
|
|
|
Date:
September 27, 2019
|
By:
|
/s/
David Moss
|
|
|
David Moss
|
|
|
Chief Financial
Officer
|
2
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Aug 2024 to Sep 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Sep 2023 to Sep 2024